---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-102137"
form_type: "8-K"
ticker: "PMN"
cik: "0001374339"
company_name: "ProMIS Neurosciences Inc."
filed_at: "2025-10-24T23:59:59+00:00"
generated_at: "2026-05-17T02:19:14.743059+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# ProMIS Neurosciences appoints Slanix Paul Alex, Pharm.D., to board of directors

## Summary
- Dr. Alex is President and Portfolio Manager for Ally Bridge Group, a major shareholder; joined board effective Oct 22, 2025.
- He receives initial option for 40,000 common shares vesting 25% immediately, rest over 36 months; annual fee $40,000.
- Company highlights upcoming data readouts from PRECISE-AD trial (PMN310) in 2Q26 and 4Q26.
- Board determined Dr. Alex is independent under Nasdaq listing standards.
- Ally Bridge Group has made multiple investments in ProMIS, including July 2025.

## SEC filing metadata
- accession: 0001104659-25-102137
- form_type: 8-K
- ticker: PMN
- cik: 0001374339
- company_name: ProMIS Neurosciences Inc.
- filed_at: 2025-10-24T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1374339/000110465925102137/0001104659-25-102137-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1374339/000110465925102137/pmn-20251022x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-102137
- JSON: https://secwatch.observer/filing/0001104659-25-102137.json
- Plain text: https://secwatch.observer/filing/0001104659-25-102137.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.